| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 23.15% | Morgan Stanley | $118 → $113 | Maintains | Overweight |
| 09/21/2023 | 8.98% | Barclays | $115 → $100 | Maintains | Overweight |
| 08/22/2023 | 20.97% | Jefferies | $113 → $111 | Maintains | Buy |
| 06/27/2023 | 28.6% | Morgan Stanley | $118 → $118 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 27.51% | Citigroup | $109 → $117 | Upgrades | Neutral → Buy |
| 04/14/2023 | 24.24% | Stifel | → $114 | Reinstates | → Buy |
| 04/13/2023 | 24.24% | Stifel | → $114 | Reinstates | → Buy |
| 03/30/2023 | 26.42% | JP Morgan | $109 → $116 | Upgrades | Neutral → Overweight |
| 03/01/2023 | 26.42% | UBS | $106 → $116 | Upgrades | Neutral → Buy |
| 02/13/2023 | 18.79% | JP Morgan | $95 → $109 | Maintains | Neutral |
| 02/02/2023 | 28.6% | Morgan Stanley | $109 → $118 | Maintains | Overweight |
| 01/25/2023 | 30.78% | Goldman Sachs | $95 → $120 | Upgrades | Neutral → Buy |
| 01/19/2023 | 28.6% | Jefferies | → $118 | Upgrades | Hold → Buy |
| 12/13/2022 | 18.79% | Citigroup | → $109 | Reinstates | → Neutral |
| 11/15/2022 | 19.88% | Argus Research | → $110 | Upgrades | Hold → Buy |
| 11/02/2022 | 18.79% | Morgan Stanley | $102 → $109 | Maintains | Overweight |
| 10/14/2022 | 14.43% | Stifel | $115 → $105 | Maintains | Buy |
| 10/14/2022 | 11.16% | Morgan Stanley | $112 → $102 | Maintains | Overweight |
| 07/19/2022 | 7.89% | Jefferies | $107 → $99 | Maintains | Hold |
| 04/22/2022 | 22.06% | Morgan Stanley | $104 → $112 | Maintains | Overweight |
| 03/25/2022 | 14.43% | Stifel | $115 → $105 | Maintains | Buy |
| 03/25/2022 | 13.34% | Morgan Stanley | $115 → $104 | Maintains | Overweight |
| 03/22/2022 | 8.98% | Goldman Sachs | $116 → $100 | Downgrades | Buy → Neutral |
| 03/07/2022 | 19.88% | JP Morgan | $130 → $110 | Downgrades | Overweight → Neutral |
| 02/17/2022 | 19.88% | UBS | $95 → $110 | Maintains | Neutral |
| 01/26/2022 | 25.33% | Morgan Stanley | $105 → $115 | Maintains | Overweight |
| 12/02/2021 | 14.43% | Morgan Stanley | $110 → $105 | Maintains | Overweight |
| 08/19/2021 | 30.78% | Deutsche Bank | $114 → $120 | Maintains | Buy |
| 05/06/2021 | 19.88% | Morgan Stanley | $105 → $110 | Maintains | Overweight |
| 04/21/2021 | 14.43% | Morgan Stanley | $103 → $105 | Maintains | Overweight |
| 04/09/2021 | 14.43% | JP Morgan | $81 → $105 | Upgrades | Neutral → Overweight |
| 02/25/2021 | 12.25% | Morgan Stanley | $94 → $103 | Maintains | Overweight |
| 01/20/2021 | 0.26% | Bernstein | → $92 | Initiates Coverage On | → Market Perform |
| 11/23/2020 | -12.82% | UBS | → $80 | Downgrades | Buy → Neutral |
| 10/07/2020 | 8.98% | Citigroup | $82 → $100 | Upgrades | Neutral → Buy |
| 09/11/2020 | 0.26% | B of A Securities | $90 → $92 | Maintains | Buy |
| 04/29/2020 | -7.37% | UBS | $70 → $85 | Maintains | Buy |
| 04/07/2020 | -15% | Citigroup | $90 → $78 | Maintains | Neutral |
| 04/01/2020 | -12.82% | Goldman Sachs | → $80 | Reinstates | → Buy |
| 03/18/2020 | 1.35% | Morgan Stanley | $99 → $93 | Maintains | Overweight |
| 02/13/2020 | 11.16% | Cowen & Co. | $90 → $102 | Upgrades | Market Perform → Outperform |
| 02/06/2020 | 8.98% | CFRA | $90 → $100 | Reiterates | → Buy |
| 01/07/2020 | 24.24% | Piper Sandler | $105 → $114 | Maintains | Overweight |
| 12/16/2019 | 7.89% | Morgan Stanley | $92 → $99 | Maintains | Overweight |
| 12/02/2019 | — | Citigroup | Downgrades | Buy → Neutral | |
| 10/18/2019 | 8.98% | Wells Fargo | $102 → $100 | Maintains | Outperform |
| 10/14/2019 | -1.92% | Citigroup | $110 → $90 | Maintains | Buy |
| 10/01/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 07/19/2019 | 8.98% | Barclays | $82 → $100 | Upgrades | Equal-Weight → Overweight |
| 07/12/2019 | -6.28% | Morgan Stanley | $94 → $86 | Maintains | Overweight |
| 05/23/2019 | -10.64% | Barclays | $67 → $82 | Upgrades | Underweight → Equal-Weight |
| 05/17/2019 | 2.44% | B of A Securities | $81 → $94 | Upgrades | Underperform → Neutral |
| 04/15/2019 | 2.44% | Morgan Stanley | $88 → $94 | Maintains | Overweight |
| 02/27/2019 | — | UBS | Upgrades | Neutral → Buy | |
| 01/08/2019 | -12.82% | Morgan Stanley | $102 → $80 | Maintains | Overweight |
| 12/18/2018 | -19.35% | Credit Suisse | $92 → $74 | Downgrades | Neutral → Underperform |
| 10/19/2018 | 8.98% | Citigroup | $95 → $100 | Maintains | Buy |
| 10/16/2018 | 5.71% | Bernstein | → $97 | Initiates Coverage On | → Outperform |
What is the target price for Philip Morris Intl (PM)?
The latest price target for Philip Morris Intl (NYSE: PM) was reported by Morgan Stanley on October 2, 2023. The analyst firm set a price target for $113.00 expecting PM to rise to within 12 months (a possible 23.15% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Philip Morris Intl (PM)?
The latest analyst rating for Philip Morris Intl (NYSE: PM) was provided by Morgan Stanley, and Philip Morris Intl maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Philip Morris Intl (PM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Philip Morris Intl, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Philip Morris Intl was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
Is the Analyst Rating Philip Morris Intl (PM) correct?
While ratings are subjective and will change, the latest Philip Morris Intl (PM) rating was a maintained with a price target of $118.00 to $113.00. The current price Philip Morris Intl (PM) is trading at is $91.76, which is out of the analyst's predicted range.